6/17
07:15 pm
rlmd
Relmada Therapeutics Inc. (NASDAQ: RLMD) Under Investigation By Schall Law Firm For Potential Securities Violations. Investors Who Lost Money Encouraged To Contact The Firm
Neutral
Report
Relmada Therapeutics Inc. (NASDAQ: RLMD) Under Investigation By Schall Law Firm For Potential Securities Violations. Investors Who Lost Money Encouraged To Contact The Firm
6/11
07:45 pm
rlmd
Allegations Leveled At Cloudflare, Inc. (NYSE:NET): Schall Law Firm Begins Investigation And Calls On Impacted Investors To Reach Out
Low
Report
Allegations Leveled At Cloudflare, Inc. (NYSE:NET): Schall Law Firm Begins Investigation And Calls On Impacted Investors To Reach Out
6/11
07:45 pm
rlmd
Claims Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation And Invites Affected Investors To Get In Touch
Low
Report
Claims Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation And Invites Affected Investors To Get In Touch
6/10
07:30 am
rlmd
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
High
Report
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
6/9
11:00 am
rlmd
Accusations Made Against Relmada Therapeutics, Inc.: Schall Law Firm Commences Probe And Calls On Impacted Investors To Participate
High
Report
Accusations Made Against Relmada Therapeutics, Inc.: Schall Law Firm Commences Probe And Calls On Impacted Investors To Participate
6/8
11:00 am
rlmd
Charges Leveled At Relmada Therapeutics, Inc.: Schall Law Firm Begins Investigation And Invites Impacted Investors To Engage.
High
Report
Charges Leveled At Relmada Therapeutics, Inc.: Schall Law Firm Begins Investigation And Invites Impacted Investors To Engage.
6/7
07:00 pm
rlmd
Accusations Against Relmada Therapeutics, Inc.: Schall Law Firm Initiates Probe And Calls On Impacted Investors To Connect
Medium
Report
Accusations Against Relmada Therapeutics, Inc.: Schall Law Firm Initiates Probe And Calls On Impacted Investors To Connect
6/6
01:15 pm
rlmd
Allegations Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation and Urges Impacted Investors to Reach Out
Low
Report
Allegations Against Relmada Therapeutics, Inc.: Schall Law Firm Starts Investigation and Urges Impacted Investors to Reach Out
5/8/2024
04:05 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
-0.8%
relmada therapeutics, inc.
3/19/2024
04:15 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
-17.4%
relmada therapeutics, inc.
11/8/2023
04:01 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
-0.3%
relmada therapeutics, inc.
8/8/2023
04:01 pm
rlmd
relmada therapeutics, inc.
BEAT
Report
7.1%
relmada therapeutics, inc.
5/30
04:06 pm
rlmd
Form 8-K RELMADA THERAPEUTICS, For: May 24
Low
Report
Form 8-K RELMADA THERAPEUTICS, For: May 24
5/29
09:26 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: TRAVERSA SERGIO
Low
Report
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: TRAVERSA SERGIO
5/29
09:25 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: Shenouda Maged
Low
Report
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: Shenouda Maged
5/29
09:25 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: GLASSPOOL JOHN
Low
Report
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: GLASSPOOL JOHN
5/29
09:25 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: Kelly Paul Edward
Low
Report
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: Kelly Paul Edward
5/29
09:25 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: Fedeli Fabiana
Low
Report
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: Fedeli Fabiana
5/29
09:24 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: CASAMENTO CHARLES J
Low
Report
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: CASAMENTO CHARLES J
5/29
09:24 pm
rlmd
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: Ence Chuck
Low
Report
Form 4 RELMADA THERAPEUTICS, For: May 24 Filed by: Ence Chuck
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
10/14
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
134.0%
10/18
Form 8-K RELMADA THERAPEUTICS, For: Oct 17
52.4%
12/4
Relmada prices $100M equity offering [Seeking Alpha]
49.8%
3/18
Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J
14.7%
3/16
Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas
10.6%
10/28
Form S-3/A RELMADA THERAPEUTICS,
10.5%
3/24
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
10.0%
5/16
Form D RELMADA THERAPEUTICS,
8.2%
3/31
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
7.4%
5/15
Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward
7.1%
10/17
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
-18.0%
6/20
Form 8-K RELMADA THERAPEUTICS, For: Jun 14
-16.0%
10/21
Form 8-K RELMADA THERAPEUTICS, For: Oct 15
-12.3%
7/10
Form D/A RELMADA THERAPEUTICS,
-10.5%
1/31
Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06
-9.7%
3/9
Form 8-K RELMADA THERAPEUTICS, For: Mar 06
-8.7%
3/9
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
-8.6%
10/24
Form EFFECT RELMADA THERAPEUTICS,
-7.1%
5/1
Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-6.0%
4/21
Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock.
-6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register